Novo Taps OpenAI to Speed Development of New Obesity Drugs

Novo Nordisk A/S will integrate OpenAI’s artificial intelligence across the company to accelerate drug development.

The Danish drugmaker didn’t disclose financial terms of the partnership announced Tuesday, which adds to Novo’s existing AI efforts that include a research-focused deal announced last year with Nvidia Corp.

Novo is trying to get faster at everything from drug development to production planning as it fights to regain its share of the competitive market for obesity drugs. Though it was first to market with the current generation of powerful medicines, the company has lost share to US rival Eli Lilly & Co. ...